Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics Inc (OTLC) is a clinical-stage biopharmaceutical company advancing innovative therapies for cancer treatment through precision medicine and targeted drug development. This page consolidates official news releases and verified updates, providing stakeholders with a reliable resource for tracking the company’s progress in oncology research.
Investors and industry observers will find timely information on clinical trial milestones, regulatory developments, and strategic partnerships with pharmaceutical collaborators. The curated news feed also covers financial disclosures and operational updates critical for assessing OTLC’s position in the competitive oncology therapeutics market.
Content is organized to highlight key areas of interest including R&D advancements, technology innovations, and corporate governance updates. Regular visitors can stay informed about the company’s efforts to address unmet medical needs through its pipeline of novel cancer therapies.
Bookmark this page for direct access to Oncotelic Therapeutics’ latest announcements, or subscribe to Stock Titan’s alerts for real-time updates on OTLC’s developments in oncology research and biopharmaceutical collaborations.
Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself as a key player in the biotech industry, focusing on developing treatments for aggressive cancers and pediatric rare diseases. Under CEO Dr. Vuong Trieu's leadership, the company is leveraging artificial intelligence, nanomedicine, and novel clinical models to advance its therapeutic pipeline.
The company's intellectual property portfolio includes over 500 patent applications and 75 issued patents. Oncotelic is specifically targeting difficult-to-treat conditions such as glioblastoma and pancreatic cancer, aiming to address significant unmet medical needs in these areas through RNA-based and immunotherapy approaches.
Oncotelic Therapeutics (OTCQB: OTLC) has provided a comprehensive update on its clinical and regulatory progress over the past two years. The company's pipeline features multiple late-stage drug candidates targeting oncology and rare diseases.
Key programs include OT-101 in Phase 3 for pancreatic cancer, OXi4503 advancing to Phase 3 for AML/MDS, CA4P/Fosbretabulin for oncology, AL-101 in Phase 2 for Parkinson's and sexual dysfunctions, and AL-102 for Alzheimer's disease. The company is also developing pediatric rare disease programs and a nanomedicine pipeline utilizing the 505(b)(2) pathway for expedited approval.
Oncotelic Therapeutics (OTCQB: OTLC) highlighted the contributions of Chairman and CEO Dr. Vuong Trieu and provided an update on its clinical pipeline. Dr. Trieu, a renowned industry pioneer, has an extensive portfolio of over 500 filed patents and 75 issued patents covering various therapeutic areas.
His notable achievements include co-inventing Abraxane® (acquired for $2.9 billion) and developing Cynviloq™ (sold for $1.3 billion). The company's pipeline includes six key programs: OT-101 (Phase 3 for pancreatic cancer), OXi4503 (Phase 2 in AML/MDS), CA4P/Fosbretabulin, AL-101 (Phase 2 for Parkinson's), AL-102 (discovery stage), and pediatric rare disease programs.
Oncotelic Therapeutics (OTCQB: OTLC) showcased its robust pipeline and highlighted the intellectual property contributions of CEO Dr. Vuong Trieu. Dr. Trieu's portfolio includes over 500 filed patents and 75 issued patents, with notable achievements including co-inventing Abraxane® (acquired for $2.9 billion) and developing Cynviloq™ (sold for $1.3 billion).
The company's pipeline includes multiple clinical-stage assets: OT-101 (Phase 3 for pancreatic cancer), OXi4503 (Phase 2 in AML/MDS), CA4P/Fosbretabulin (late-stage oncology), AL-101 (Phase 2 for Parkinson's), AL-102 (discovery stage for Alzheimer's), and pediatric rare disease programs targeting orphan indications.
Oncotelic Therapeutics (OTCQB: OTLC) has highlighted a new peer-reviewed publication demonstrating the link between TGFB2 expression and survival rates in younger pancreatic cancer patients. The study revealed that high TGFB2 expression significantly reduced overall survival in patients under 65 years, with median survival of 17.9 months versus 66.9 months for those with low expression.
The research supports further evaluation of the company's investigational antisense drug OT-101 (trabedersen) as a TGFB2-targeted treatment for pancreatic ductal adenocarcinoma (PDAC). Clinical data from the OT-101 P001 PDAC study showed promising results, with a median overall survival of 12.7 months in a treated subset with low IL-6.
Oncotelic Therapeutics (OTCQB: OTLC) has published a groundbreaking study in the International Journal of Molecular Sciences identifying TGFB2 gene methylation as a positive prognostic biomarker for pancreatic ductal adenocarcinoma (PDAC). The research, conducted in collaboration with Sapu Biosciences, revealed that patients with high TGFB2 methylation and low immune markers showed a significant median overall survival exceeding 50 months.
The findings support the development of OT-101, Oncotelic's investigational antisense oligonucleotide targeting TGFB2 mRNA. The study utilized PDAOAI, the company's AI-powered chatbot platform, for literature mining and analysis, demonstrating the integration of artificial intelligence in scientific research.
Oncotelic Therapeutics (OTCQB:OTLC) announced that CEO Dr. Vuong Trieu will deliver a keynote presentation on their innovative Deciparticles™ platform at the IDDST-Europe Conference in Stockholm, June 18-20, 2025.
Deciparticles represent a breakthrough in drug delivery technology as sub-20 nm nanoparticles designed to overcome challenges in delivering insoluble drugs to solid tumors. The platform has demonstrated success in formulating over 90% of tested water-insoluble drugs, including taxanes.
Key highlights include:
- Enhanced tumor penetration and superior antitumor efficacy compared to conventional formulations
- Integration of biomarker-driven strategies using DNA methylation signatures
- Lead candidate Sapu-001 showing promising preclinical results with higher maximum-tolerated dose and reduced toxicity
The presentation is scheduled for June 19, 2025, at 10:30 CET, with Phase 1 clinical trials for Sapu-001 anticipated later in 2025.
Oncotelic Therapeutics (OTCQB:OTLC) has reported its FY 2024 financial results, marking a transformational year with significant developments. The company's joint venture, GPM Biotechnology , achieved GMP certification for its San Diego facility and obtained a Drug Manufacturing License. The facility is developing 6 nanoparticle compounds, including OT-101, with two compounds approaching IND filing stage.
The company has partnered with Shanghai Medicilon to utilize their rapid IND platform for up to 20 new filings. OT-101 is currently in Phase 3 trials for pancreatic cancer and has completed a phase 1 combination trial with IL-2. The company has also launched PDAOAI, an AI platform specifically designed for pharmaceutical regulatory processes.
Financially, OTLC reported a reduced net loss of $4.52M in FY 2024, compared to $7.90M in FY 2023. The improvement was primarily due to lower goodwill impairment ($2.9M decrease) and reduced general administrative expenses. The company recorded no service revenue in 2024, compared to $70,000 in 2023.
Oncotelic Therapeutics (OTCQB:OTLC) has published groundbreaking research on glioblastoma (GBM) treatment, revealing that high TGFB2 gene methylation correlates with improved overall survival in patients, surpassing the predictive value of MGMT and TGFB1 methylation.
The study identified several genes and pathways linked to TGFB2 methylation that improve survival outcomes, including T-cell activation, antigen processing, and Toll-like receptor pathways. The research also found that MALT1 mRNA negatively impacted survival rates, suggesting a potential target for therapy.
To facilitate research collaboration, Oncotelic has launched its proprietary PDAOAI communication platform, allowing researchers to interact with the paper and referenced articles through a single interface. This marks the company's first publication utilizing their proprietary AI technology.
Oncotelic Therapeutics (OTCQB:OTLC) has successfully completed a Phase 1 clinical trial evaluating OT-101 in combination with IL-2 for advanced or metastatic solid tumors. The trial demonstrated a tolerable safety profile with no unexpected safety signals at the planned dosing schedule.
The company presented these findings at the 5th Symposium on World Cancer Research (SWCR) 2025, where CEO Dr. Vuong Trieu discussed TGFβ2's role in immune suppression and OT-101's development progress. Key developments include:
- OT-101 is currently in a Phase 3 STOP-PC study for pancreatic cancer, combined with mFOLFIRINOX
- The company plans to advance OT-101 plus IL-2 into further clinical studies with checkpoint inhibitors
- Future trials will explore combinations in solid tumors including lung cancer, melanoma, and colorectal cancer
FAQ
What is the current stock price of Oncotelic Therapeutics (OTLC)?
What is the market cap of Oncotelic Therapeutics (OTLC)?
